Remnants of chylomicron and very low density lipoprotein impair endothelium-dependent vasorelaxation.
Remnants of chylomicron and very low density lipoprotein (VLDL) have been implicated as potentially atherogenic. Since endothelial dysfunction is an early event in atherosclerosis, we examined effects of the remnants on endothelium-dependent vasorelaxation. The remnant lipoproteins were isolated from postprandial plasma in hyperlipidemic subjects using the immunoaffinity gel mixture of anti apo A-1 and anti apo B-100 monoclonal antibodies and ultracentrifugation. Rabbit aortic strips suspended in the organ chambers were incubated for 2 h with the preparations of lipoproteins and lipids. After incubation, the strips were tested with vasodilators after precontraction with phenylephrine (1 microM). The remnant lipoproteins (750-1500 microg triglyceride/ml) but not VLDL fraction (up to 1500 microg triglyceride/ml) impaired vasorelaxation in responses to acetylcholine, substance P and A23187. Carbamylated or methylated remnant lipoproteins, chemically modified remnant lipoproteins, had comparable impairment of the vasorelaxation as unmodified remnant lipoproteins. Incubation with lipid extracts from the remnant lipoproteins also exerted an inhibitory effect on the vasorelaxation. Relaxation to sodium nitroprusside was fully preserved in all aortas exposed to the lipoprotein preparations. Thus, the remnant lipoproteins impair endothelium-dependent arterial relaxation at the concentrations observed in the plasma in patients with coronary artery disease (500-2000 microg triglyceride of remnant lipoprotein/ml). The impairment may be in apoprotein receptor-independent manner, and the lipids in the remnants seem to contribute to the inhibitory effect. The endothelial dysfunction caused by the remnant lipoproteins may play a role in the high prevalence of atherosclerotic coronary artery disease in postprandial hyperlipidemic patients.
Doi
H
H
Division of Cardiology, Kumamoto University School of Medicine, Kumamoto City, Japan.
Kugiyama
K
K
Ohgushi
M
M
Sugiyama
S
S
Matsumura
T
T
Ohta
Y
Y
Nakano
T
T
Nakajima
K
K
Yasue
H
H
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D000001:Calcimycin / Q000494:pharmacology; D002478:Cells, Cultured; D002914:Chylomicrons / Q000494:pharmacology*; D004587:Electrophoresis, Agar Gel; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007476:Ionophores / Q000494:pharmacology; D008079:Lipoproteins, VLDL / Q000494:pharmacology*; D008297:Male; D011817:Rabbits; D014471:Umbilical Veins / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology*
D002914:Chylomicrons; D007476:Ionophores; D008079:Lipoproteins, VLDL; D000001:Calcimycin; D000109:Acetylcholine